David Hochman Acquires 5,000 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider David Hochman purchased 5,000 shares of the business’s stock in a transaction on Friday, May 15th. The stock was acquired at an average price of $3.77 per share, with a total value of $18,850.00. Following the completion of the acquisition, the insider directly owned 1,059,029 shares in the company, valued at $3,992,539.33. The trade was a 0.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Orchestra BioMed Stock Performance

Orchestra BioMed stock opened at $3.98 on Tuesday. The firm has a market capitalization of $238.32 million, a P/E ratio of -4.10 and a beta of 0.52. The stock has a fifty day moving average price of $4.28 and a 200 day moving average price of $4.27. Orchestra BioMed Holdings, Inc. has a 52 week low of $2.20 and a 52 week high of $5.42. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%. Equities research analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.62 earnings per share for the current year.

Key Orchestra BioMed News

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: Director Eric Fain bought 20,000 shares at $4.13 each, a $82,600 purchase that increased his stake by 27.89%. Insider buying can signal management confidence in the company’s outlook. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $10 price target, while raising several earnings estimates for 2026 and 2027. The higher forecast for Q2 2026 EPS and improved longer-term projections suggest analysts see somewhat better fundamentals ahead. Article Title
• Neutral Sentiment: HC Wainwright’s updated estimates still show losses for every quarter and year covered, so the company remains unprofitable in the near term despite the upgrades. Article Title
• Neutral Sentiment: Recent analyst commentary remains mixed overall, with some firms maintaining bullish ratings while others have downgraded the stock, keeping sentiment somewhat split. Article Title

Institutional Investors Weigh In On Orchestra BioMed

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after acquiring an additional 324,558 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Orchestra BioMed during the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC purchased a new stake in Orchestra BioMed during the 3rd quarter worth $2,495,000. Geode Capital Management LLC boosted its position in Orchestra BioMed by 22.4% during the 4th quarter. Geode Capital Management LLC now owns 473,363 shares of the company’s stock worth $1,965,000 after purchasing an additional 86,564 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Orchestra BioMed by 46.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 263,788 shares of the company’s stock valued at $1,095,000 after purchasing an additional 83,349 shares in the last quarter. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OBIO has been the subject of a number of recent analyst reports. Barclays boosted their target price on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Chardan Capital reiterated a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a report on Thursday, March 12th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Orchestra BioMed in a research note on Thursday, May 14th. Weiss Ratings downgraded Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Finally, Wall Street Zen lowered Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Orchestra BioMed presently has a consensus rating of “Moderate Buy” and an average target price of $14.50.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.